系统性红斑狼疮靶向治疗研究进展

doi:10.35541/cjd.20240530

中华皮肤科杂志 ›› 2025, e20240530.doi: 10.35541/cjd.20240530

系统性红斑狼疮靶向治疗研究进展

薛珂陈佳李斌

同济大学附属皮肤病医院风湿免疫科，上海 200443

收稿日期:2024-10-09 修回日期:2025-03-12 发布日期:2025-06-04
通讯作者: 陈佳 E-mail:1500155@tongji.edu.cn

Targeted therapy for systemic lupus erythematosus

Xue Ke, Chen Jia, Li Bin

Department of Rheumatology, Skin Disease Hospital of Tongji University, Shanghai 200443, China

Received:2024-10-09 Revised:2025-03-12 Published:2025-06-04
Contact: Chen Jia E-mail:1500155@tongji.edu.cn

摘要/Abstract

摘要： 【摘要】系统性红斑狼疮（SLE）治疗靶点的挖掘一直是国内外的研究热点。近年来，随着对红斑狼疮发病机制认识的逐步深入，贝利尤单抗、泰它西普、阿尼鲁单抗均已临床应用。此外，靶向B细胞/浆细胞其他靶点、T细胞、中性粒细胞、多个炎症信号通路的治疗药物层出不穷。本文结合最新临床试验，综述SLE靶向治疗的研究进展，为SLE个体化治疗提供一定依据。

关键词: 红斑狼疮, 系统性, 靶向治疗, 生物制剂, 临床试验

Abstract: 【Abstract】 The exploration of novel targeted therapies for systemic lupus erythematosus （SLE） has always been a research hot topic in China and other countries. In recent years, there has been an increasingly in?depth understanding of the pathogenesis of SLE. The approval of belimumab, telitacicept, and anifrolumab for clinical applications marked a breakthrough in the treatment of SLE. In addition, novel agents targeting other B?cell/plasma cell antigens, T cells, neutrophils, and multiple inflammatory signaling pathways are emerging, which may provide more treatment options for SLE. This review summarizes research progress in targeted therapies for SLE based on the latest clinical trials, providing a basis for individualized treatment of SLE.

Key words: Lupus erythematosus, systemic, Targeted treatment, Biologic agent, Clinical trial

薛珂陈佳李斌. 系统性红斑狼疮靶向治疗研究进展[J]. 中华皮肤科杂志, 2025,e20240530. doi:10.35541/cjd.20240530

Xue Ke, Chen Jia, Li Bin. Targeted therapy for systemic lupus erythematosus[J]. Chinese Journal of Dermatology,2025,e20240530. doi:10.35541/cjd.20240530

参考文献 36

［1］	Accapezzato D, Caccavale R, Paroli MP, et al. Advances in the pathogenesis and treatment of systemic lupus erythematosus［J］. Int J Mol Sci, 2023,24（7）:6578. doi: 10.3390/ijms24076578.
［2］	Navarra SV, Guzmán RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo⁃controlled, phase 3 trial［J］. Lancet, 2011,377（9767）:721⁃731. doi: 10.1016/S0140⁃6736（10）61354⁃2.
［3］	Furie R, Petri M, Zamani O, et al. A phaseⅢ, randomized, placebo⁃controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus［J］. Arthritis Rheum, 2011,63（12）:3918⁃3930. doi: 10.1002/art.30613.
［4］	Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately⁃to⁃severely active systemic lupus erythematosus: the randomized, double⁃blind, phaseⅡ/Ⅲ systemic lupus erythematosus evaluation of rituximab trial［J］. Arthritis Rheum, 2010,62（1）:222⁃233. doi: 10.1002/art.27233.
［5］	Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study［J］. Arthritis Rheum, 2012,64（4）:1215⁃1226. doi: 10.1002/art.34359.
［6］	中华医学会风湿病学分会, 国家皮肤与免疫疾病临床医学研究中心, 中国系统性红斑狼疮研究协作组. 2020中国系统性红斑狼疮诊疗指南［J］. 中华内科杂志, 2020,59（3）:172⁃185. doi: 10.3760/cma.j.issn.0578⁃1426.2020.03.002.
［7］	Kraaij T, Arends EJ, van Dam LS, et al. Long⁃term effects of combined B⁃cell immunomodulation with rituximab and belimumab in severe, refractory systemic lupus erythematosus: 2⁃year results［J］. Nephrol Dial Transplant, 2021,36（8）:1474⁃1483. doi: 10.1093/ndt/gfaa117.
［8］	Atisha⁃Fregoso Y, Malkiel S, Harris KM, et al. PhaseⅡ randomized trial of rituximab plus cyclophosphamide followed by belimumab for the treatment of lupus nephritis［J］. Arthritis Rheumatol, 2021,73（1）:121⁃131. doi: 10.1002/art.41466.
［9］	Merrill JT, Guthridge J, Smith M, et al. Obexelimab in systemic lupus erythematosus with exploration of response based on gene pathway co⁃expression patterns: a double⁃blind, randomized, placebo⁃controlled, phase 2 trial［J］. Arthritis Rheumatol, 2023,75（12）:2185⁃2194. doi: 10.1002/art.42652.
［10］	Mougiakakos D, Krönke G, Völkl S, et al. CD19⁃targeted CAR T cells in refractory systemic lupus erythematosus［J］. N Engl J Med, 2021,385（6）:567⁃569. doi: 10.1056/NEJMc2107725.
［11］	Mackensen A, Müller F, Mougiakakos D, et al. Anti⁃CD19 CAR T cell therapy for refractory systemic lupus erythematosus［J］. Nat Med, 2022,28（10）:2124⁃2132. doi: 10.1038/s41591⁃022⁃02017⁃5.
［12］	Mougiakakos D. Allogeneic CAR T cells for autoimmune diseases: a glimpse into the future［J］. Signal Transduct Target Ther, 2024,9（1）:276. doi: 10.1038/s41392⁃024⁃01998⁃8.
［13］	Wang L, Yin H, Jiang J, et al. A rationally designed CD19 monoclonal antibody⁃triptolide conjugate for the treatment of systemic lupus erythematosus［J］. Acta Pharm Sin B, 2024,14（10）:4560⁃4576. doi: 10.1016/j.apsb.2024.06.024.
［14］	Alexander T, Krönke J, Cheng Q, et al. Teclistamab⁃induced remission in refractory systemic lupus erythematosus［J］. N Engl J Med, 2024,391（9）:864⁃866. doi: 10.1056/NEJMc2407150.
［15］	Isenberg D, Furie R, Jones NS, et al. Efficacy, safety, and pharmacodynamic effects of the Bruton's tyrosine kinase inhibitor fenebrutinib （GDC⁃0853） in systemic lupus erythematosus: results of a phaseⅡ, randomized, double⁃blind, placebo⁃controlled trial［J］. Arthritis Rheumatol, 2021,73（10）:1835⁃1846. doi: 10.1002/art.41811.
［16］	Wallace DJ, Dörner T, Pisetsky DS, et al. Efficacy and safety of the Bruton's tyrosine kinase inhibitor evobrutinib in systemic lupus erythematosus: results of a phaseⅡ, randomized, double⁃blind, placebo⁃controlled dose⁃ranging trial［J］. ACR Open Rheumatol, 2023,5（1）:38⁃48. doi: 10.1002/acr2.11511.
［17］	Merrill JT, Burgos⁃Vargas R, Westhovens R, et al. The efficacy and safety of abatacept in patients with non⁃life⁃threatening manifestations of systemic lupus erythematosus: results of a twelve⁃month, multicenter, exploratory, phase Ⅱb, randomized, double⁃blind, placebo⁃controlled trial［J］. Arthritis Rheum, 2010,62（10）:3077⁃3087. doi: 10.1002/art.27601.
［18］	Furie RA, Leon G, Thomas M, et al. A phase 2, randomised, placebo⁃controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate⁃to⁃severe systemic lupus erythematosus, the PEARL⁃SC study［J］. Ann Rheum Dis, 2015,74（9）:1667⁃1675. doi: 10.1136/annrheumdis⁃2013⁃205144.
［19］	低剂量白细胞介素⁃2治疗系统性红斑狼疮专家组. 低剂量白细胞介素⁃2治疗系统性红斑狼疮的推荐意见［J］. 中华风湿病学杂志, 2019,23（1）:5⁃9. doi: 10.3760/cma.j.issn.1007⁃7480. 2019.01.002.
［20］	Miao N, Wang Z, Wang Q, et al. Oxidized mitochondrial DNA induces gasdermin D oligomerization in systemic lupus erythematosus［J］. Nat Commun, 2023,14（1）:872. doi: 10.1038/s41467⁃023⁃36522⁃z.
［21］	Li P, Jiang M, Li K, et al. Glutathione peroxidase 4⁃regulated neutrophil ferroptosis induces systemic autoimmunity［J］. Nat Immunol, 2021,22（9）:1107⁃1117. doi: 10.1038/s41590⁃021⁃00993⁃3.
［22］	Crow MK. Pathogenesis of systemic lupus erythematosus: risks, mechanisms and therapeutic targets［J］. Ann Rheum Dis, 2023,82（8）:999⁃1014. doi: 10.1136/ard⁃2022⁃223741.
［23］	Vital EM, Merrill JT, Morand EF, et al. Anifrolumab efficacy and safety by typeⅠ interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phaseⅢ trials［J］. Ann Rheum Dis, 2022,81（7）:951⁃961. doi: 10.1136/annrheumdis⁃2021⁃221425.
［24］	Illei GG, Shirota Y, Yarboro CH, et al. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open⁃label phaseⅠdosage⁃escalation study［J］. Arthritis Rheum, 2010,62（2）:542⁃552. doi: 10.1002/art.27221.
［25］	Lorenzo⁃Vizcaya A, Isenberg DA. Clinical trials in systemic lupus erythematosus: the dilemma⁃why have phaseⅢ trials failed to confirm the promising results of phaseⅡ trials?［J］. Ann Rheum Dis, 2023,82（2）:169⁃174. doi: 10.1136/ard⁃2022⁃222839.
［26］	Yin H, Li L, Feng X, et al. 2D4, a humanized monoclonal antibody targeting CD132, is a promising treatment for systemic lupus erythematosus［J］. Signal Transduct Target Ther, 2024,9（1）:323. doi: 10.1038/s41392⁃024⁃02017⁃6.
［27］	Rovin BH, Teng Y, Ginzler EM, et al. Efficacy and safety of voclosporin versus placebo for lupus nephritis （AURORA 1）: a double⁃blind, randomised, multicentre, placebo⁃controlled, phase 3 trial［J］. Lancet, 2021,397（10289）:2070⁃2080. doi: 10.1016/S0140⁃6736（21）00578⁃X.
［28］	Furie RA, van Vollenhoven RF, Kalunian K, et al. Trial of anti⁃BDCA2 antibody litifilimab for systemic lupus erythematosus［J］. N Engl J Med, 2022,387（10）:894⁃904. doi: 10.1056/NEJMoa2118025.
［29］	Piranavan P, Perl A. Improvement of renal and non⁃renal SLE outcome measures on sirolimus therapy ⁃ a 21⁃year follow⁃up study of 73 patients［J］. Clin Immunol, 2021,229:108781. doi: 10.1016/j.clim.2021.108781.
［30］	Zhang J, Guo Q, Dai D, et al. Rapamycin⁃encapsulated costimulatory ICOS/CD40L⁃bispecific nanoparticles restrict pathogenic helper T⁃B⁃cell interactions while in situ suppressing mTOR for lupus treatment［J］. Biomaterials, 2022,289:121766. doi: 10.1016/j.biomaterials.2022.121766.
［31］	Wang H, Li T, Sun F, et al. Safety and efficacy of the SGLT2 inhibitor dapagliflozin in patients with systemic lupus erythematosus: a phaseⅠ/Ⅱ trial［J］. RMD Open, 2022,8（2）:e002686. doi: 10.1136/rmdopen⁃2022⁃002686.
［32］	Klopp⁃Schulze L, Shaw JV, Dong JQ, et al. Applying modeling and simulations for rational dose selection of novel Toll⁃like receptor 7/8 inhibitor enpatoran for indications of high medical need［J］. Clin Pharmacol Ther, 2022,112（2）:297⁃306. doi: 10. 1002/cpt.2606.
［33］	Gao X, Song Y, Du P, et al. Administration of a microRNA⁃21 inhibitor improves the lupus⁃like phenotype in MRL/lpr mice by repressing Tfh cell⁃mediated autoimmune responses［J］. Int Immunopharmacol, 2022,106:108578. doi: 10.1016/j.intimp.2022. 108578.
［34］	Kawato Y, Fukahori H, Nakamura K, et al. Potential benefit of the cathepsin S inhibitor, ASP1617, as a treatment for systemic lupus erythematosus［J］. Eur J Pharmacol, 2022,919:174826. doi: 10.1016/j.ejphar.2022.174826.
［35］	Xia Y, Jiang C, Yang M, et al. SB431542 alleviates lupus nephritis by regulating B cells and inhibiting the TLR9/TGFβ1/PDGFB signaling［J］. J Autoimmun, 2022,132:102894. doi: 10. 1016/j.jaut.2022.102894.
［36］	Knapp J, Braunstein M, Berg S, et al. HSPB5 suppresses renal inflammation and protects lupus⁃prone NZB/W F1 mice from severe renal damage［J］. Arthritis Res Ther, 2022,24（1）:267. doi: 10.1186/s13075⁃022⁃02958⁃9.

[1]	中国医师协会皮肤科医师分会中华医学会皮肤病学分会治疗学组中国医疗保健国际交流促进会皮肤医学分会国家皮肤与免疫疾病临床医学研究中心中国罕见病联盟皮肤罕见病专业委员会. 大疱性类天疱疮诊疗专家共识（2025版）[J]. 中华皮肤科杂志, 2025, 58(5): 405-415.
[2]	白璐楚妍刘园园朱才勇. 慢性手部湿疹的治疗进展[J]. 中华皮肤科杂志, 2025, 58(5): 477-480.
[3]	李紫钰鲁严. 关注新型冠状病毒感染后重症皮肤病[J]. 中华皮肤科杂志, 2025, 58(4): 378-383.
[4]	许秋云纪超. 坏疽性脓皮病系统合并症的研究进展[J]. 中华皮肤科杂志, 2025, 58(4): 369-373.
[5]	吕铭悦满孝勇. 细胞治疗在系统性红斑狼疮中的应用[J]. 中华皮肤科杂志, 2025, 58(4): 374-377.
[6]	木葵郭慧文海泉龙海刘昱罗帅寒天黄馨周星雨肖嵘李亚萍. 基于标准治疗联合泰它西普治疗25例系统性红斑狼疮的疗效和安全性分析[J]. 中华皮肤科杂志, 2025, 58(4): 322-327.
[7]	王文秋李承新王睿. 生物制剂治疗银屑病复发的研究现状[J]. 中华皮肤科杂志, 2025, 0(3): 20230301-e20230301.
[8]	蒋佳怡王大光. 系统性疾病致甲改变机制研究进展[J]. 中华皮肤科杂志, 2025, 58(3): 282-285.
[9]	王彩霞徐凡石晶朱海莲卢桂玲王红梅. 奥马珠单抗和度普利尤单抗治疗大疱性类天疱疮的疗效和安全性系统综述[J]. 中华皮肤科杂志, 2025, 0(3): 20220929-e0220929.
[10]	罗帅寒天龙海陆前进. 2024年系统性红斑狼疮研究新进展[J]. 中华皮肤科杂志, 2025, 0(3): 20240689-e20240689.
[11]	许焯红胡煜顾恒. 间充质干细胞来源的外泌体在皮肤病中的作用[J]. 中华皮肤科杂志, 2025, 0(3): 20220881-e20220881.
[12]	李翔倩张建中周城. 系统小分子药物和生物制剂治疗斑秃的临床研究进展[J]. 中华皮肤科杂志, 2025, 0(3): 20240247-e20240247.
[13]	黄晓燕粟娟陈明亮陈翔肖易沈敏学. 纳洛酮改善慢性砷暴露相关瘙痒人群健康相关生活质量的效果：一项随机、双盲、安慰剂对照试验[J]. 中华皮肤科杂志, 2025, 58(2): 161-166.
[14]	金兰邱云王唯嘉康晓静丁媛. [开放获取] 生物制剂治疗老年中重度银屑病124例的临床疗效和安全性回顾分析[J]. 中华皮肤科杂志, 2025, 58(1): 47-52.
[15]	王博郑捷. 老年银屑病和特应性皮炎患者生物制剂及小分子药物治疗中应注意的问题[J]. 中华皮肤科杂志, 2025, 58(1): 72-75.

系统性红斑狼疮靶向治疗研究进展

Targeted therapy for systemic lupus erythematosus

PDF

PDF (Mobile)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 36

相关文章 15

Metrics

本文评价

推荐阅读 0